Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium-Reference-Cited by-同舟云学术

Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium

Published:2019-02-27 Issue:4 Volume:145 Page:1063-1073
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Guan Jun,Darb-Esfahani Silvia,Richter Rolf,Taube Eliane T.,Ruscito Ilary,Mahner Sven,Woelber Linn,Prieske Katharina,Concin Nicole,Vergote Ignace,Van Nieuwenhuysen Els,Achimas-Cadariu Patriciu,Glajzer Joanna,Woopen Hannah,Stanske Mandy,Kulbe Hagen,Denkert Carsten,Sehouli Jalid,Braicu Elena Ioana^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-019-02877-4/fulltext.html

Reference44 articles.

1. Alam A, Herault JP, Barron P, Favier B, Fons P, Delesque-Touchard N, Senegas I, Laboudie P, Bonnin J, Cassan C et al (2004) Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. Biochem Biophys Res Commun 324(2):909–915

2. Avril S, Dincer Y, Malinowsky K, Wolff C, Gundisch S, Hapfelmeier A, Boxberg M, Bronger H, Becker KF, Schmalfeldt B (2017) Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. Oncotarget 8(58):97851–97861

3. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E, Barrowdale D, McGuffog L et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307(4):382–390

4. Bowtell DD, Böhm S, Ahmed AA, Aspuria P-J, Bast Jr RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA et al (2015) Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668

5. Braicu EI, Sehouli J, Richter R, Pietzner K, Lichtenegger W, Fotopoulou C (2012) Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome. Eur J Cancer 48(5):687–694

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics;Expert Opinion on Pharmacotherapy;2023-12-12

2. SULF1 Activates the VEGFR2/PI3K/AKT Pathway to Promote the Development of Cervical Cancer;Current Cancer Drug Targets;2023-08-04

3. Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer;JAMA Network Open;2023-08-02

4. VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial;Lung Cancer;2023-08

5. SULF1 promotes malignancy potential of cervical cancer by activating VEGFR2/PI3K/AKT signaling pathway;2023-06-09